A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera
Introduction:Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV).Methods:A total of 34 patients with PV from 18 different centers were included in th...
Main Authors: | İstemi Serin, Mehmet Hilmi Doğu, Ömer Ekinci, Gülsüm Akgün Çağlıyan, Abdulkadir Baştürk, Merih Reis Aras, Sinan Demircioğlu, Burhan Turgut, Mustafa Merter, Sibel Kabukçu Hacıoğlu, Metin Bağcı, Murat Albayrak, Serdal Korkmaz, Mehmet Ali Erkurt, Mehmet Sinan Dal, Fadime Ersoy Dursun, Anıl Tombak, İsmet Aydoğdu, Turgay Ulaş, Fevzi Altuntaş |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayinevi
2023-05-01
|
Series: | İstanbul Medical Journal |
Subjects: | |
Online Access: |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/a-real-life-turkish-experience-of-ruxolitinib-in-p/60509
|
Similar Items
-
Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib
by: Sakiyama E, et al.
Published: (2020-04-01) -
Ruxolitinib: a targeted treatment option for patients with polycythemia vera
by: Vaddi K, et al.
Published: (2016-05-01) -
Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation
by: Leona Dold, et al.
Published: (2021-09-01) -
Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
by: Stine Ulrik Mikkelsen, et al.
Published: (2018-08-01) -
Polycythemia Vera (PV): Update on Emerging Treatment Options
by: Benevolo G, et al.
Published: (2021-03-01)